New Research Study on Ocular Hypertension - Pipeline Review: Key Players involved in the research - Aerie Pharmaceuticals Inc, Allergan Plc, Angelini Group, Can-Fite BioPharma Ltd

A new independent 130 page research with title 'Ocular Hypertension - Pipeline Review, H2 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Aerie Pharmaceuticals Inc, Allergan Plc, Angelini Group, Can-Fite BioPharma Ltd, D. Western Therapeutics Institute Inc, Ironwood Pharmaceuticals Inc, Kowa Co Ltd, Laboratorios SALVAT SA, Laboratorios Sophia SA de CV, Lee's Pharmaceutical Holdings Ltd, Neurim Pharmaceuticals Ltd, NicOx SA, Novartis AG, Ocular Therapeutix Inc, Santen Pharmaceutical Co Ltd, Senju Pharmaceutical Co Ltd, Shire Plc, Sun Pharma Advanced Research Company Ltd, Sylentis SAU, Taejoon Pharm Co Ltd With n-number of tables and figures examining the Ocular Hypertension, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

Request a sample report @ https://www.htfmarketreport.com/sample-report/1317040-ocular-hypertension-pipeline-review-5

Summary
Ocular Hypertension - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H2 2018, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 9, 14, 2 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/1317040-ocular-hypertension-pipeline-review-5

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

Aerie Pharmaceuticals Inc
Allergan Plc
Angelini Group
Can-Fite BioPharma Ltd
D. Western Therapeutics Institute Inc
Ironwood Pharmaceuticals Inc
Kowa Co Ltd
Laboratorios SALVAT SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
Neurim Pharmaceuticals Ltd
NicOx SA
Novartis AG
Ocular Therapeutix Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd

Table of Contents
Table of Contents 2
Introduction 5
Ocular Hypertension - Overview 6
Ocular Hypertension - Therapeutics Development 7
Ocular Hypertension - Therapeutics Assessment 16
Ocular Hypertension - Companies Involved in Therapeutics Development 25
Ocular Hypertension - Drug Profiles 35
Ocular Hypertension - Dormant Projects 112
Ocular Hypertension - Discontinued Products 114
Ocular Hypertension - Product Development Milestones 116
Appendix 125List of Tables
Number of Products under Development for Ocular Hypertension, H2 2018
Number o

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1317040-ocular-hypertension-pipeline-review-5

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=1317040

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
www.linkedin.com/company/13388569/
www.facebook.com/htfmarketintelligence/
twitter.com/htfmarketreport
plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author

This release was published on openPR.